According to FLINT and REGENERATE trials, remarkable improvements were noted in the fibrosis of patients with NASH after being treated with FXR ligands, but no substantial changes were observed in regression in NASH (78, 79). Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.